- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00077467
Bortezomib in Treating Young Patients With Refractory or Recurrent Leukemia
A Phase I Study of PS-341 (Velcade, Bortezomib) in Pediatric Patients With Refractory/Recurrent Leukemias
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
OBJECTIVES: Primary I. Determine the maximum tolerated dose and recommended phase II dose of bortezomib in children with refractory or recurrent leukemia.
II. Determine the toxic effects of this drug in these patients. III. Determine the pharmacokinetics of this drug in these patients.
Secondary I. Determine, preliminarily, the antitumor activity of this drug in these patients.
II. Determine, preliminarily, the biologic activity of this drug in these patients.
OUTLINE: This is a dose-escalation, open-label, multicenter study.
Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of bortezomib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
PROJECTED ACCRUAL: A total of 3-36 patients will be accrued for this study within 1.5-36 months.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Arcadia, California, United States, 91006-3776
- COG Phase I Consortium
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Histologically confirmed leukemia of 1 of the following types:
- Acute lymphoblastic leukemia
- Acute myeloid leukemia
- Chronic myelogenous leukemia in blast crisis
- Relapsed or refractory disease
- Immunophenotypically confirmed disease, either at initial diagnosis or relapse
- More than 25% blasts in the bone marrow (M3 bone marrow)
- Active extramedullary disease (except leptomeningeal disease) allowed
- No known curative therapy or therapy proven to prolong survival with an acceptable quality of life available
- Performance status - Karnofsky 50-100% (for patients age 11 to 21)
- Performance status - Lansky 50-100% (for patients age 10 and under)
- Platelet count ≥ 20,000/mm^3*
- Hemoglobin ≥ 8.0 g/dL*
- WBC < 20,000/mm^3** (hydroxyurea for cytoreduction allowed)
- No hyperleukocytosis (i.e., WBC > 100,000/mm^3)
- Bilirubin ≤ 1.5 times upper limit of normal (ULN)
- ALT ≤ 5 times ULN
- Albumin ≥ 2 g/dL
- Creatinine clearance or radioisotope glomerular filtration rate ≥ 70 mL/min
Creatinine based on age as follows:
- ≤ 0.8 mg/dL for patients age 5 and under
- ≤ 1.0 mg/dL for patients age 6 to 10
- ≤ 1.2 mg/dL for patients age 11 to 15
- ≤ 1.5 mg/dL for patients age 16 to 21
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No uncontrolled infection
- Recovered from prior immunotherapy
- At least 7 days since prior filgrastim (G-CSF) or sargramostim (GM-CSF)
- At least 7 days since prior biologic agents
- At least 3 months since prior stem cell transplantation or rescue and no evidence of active graft-versus-host disease
- No concurrent prophylactic G-CSF during course 1 of study
- No concurrent immunotherapy
- No concurrent biologic therapy
- Recovered from prior chemotherapy
- At least 24 hours since prior hydroxyurea for cytoreduction
- At least 6 weeks since prior nitrosoureas
- No concurrent chemotherapy
- At least 7 days since prior steroids (except as premedication prior to blood product transfusion)
- Recovered from prior radiotherapy
- At least 2 weeks since prior small port local palliative radiotherapy
- At least 3 months since prior total body irradiation, craniospinal irradiation, or irradiation to more than 50% of the pelvis
- At least 6 weeks since other prior substantial bone marrow radiotherapy
- No concurrent radiotherapy
- At least 7 days since prior retinoids
- No other concurrent investigational agents
- No other concurrent anticancer agents
No concurrent anticonvulsant medications known to activate the cytochrome p450 system (e.g., phenytoin, carbamazepine, or phenobarbital)
- Concurrent benzodiazepines and gabapentin are allowed
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm I
Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11.
Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
|
Correlative studies
Correlative studies
Other Names:
Given IV
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Maximum tolerated dose and recommended phase II dose
Time Frame: Up to 21 days
|
Up to 21 days
|
Toxicity as assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) 3.0
Time Frame: Up to 2 years
|
Up to 2 years
|
Pharmacokinetics as assessed by confidence intervals (CI), area under the curve (AUC), and half-life (T ½)
Time Frame: Pretreatment, days 1, 8, 18-22 of course 1
|
Pretreatment, days 1, 8, 18-22 of course 1
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Antitumor activity
Time Frame: Up to 2 years
|
Up to 2 years
|
Correlate apoptosis and NF-kB activation
Time Frame: Prestudy, days 8 and 18
|
Prestudy, days 8 and 18
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Terzah Horton, COG Phase I Consortium
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Disease Attributes
- Bone Marrow Diseases
- Hematologic Diseases
- Myeloproliferative Disorders
- Neoplastic Processes
- Leukemia, Lymphoid
- Cell Transformation, Neoplastic
- Carcinogenesis
- Leukemia, Myeloid, Acute
- Leukemia
- Leukemia, Myeloid
- Recurrence
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Blast Crisis
- Leukemia, Promyelocytic, Acute
- Antineoplastic Agents
- Bortezomib
Other Study ID Numbers
- NCI-2012-01809
- U01CA097452 (U.S. NIH Grant/Contract)
- ADVL0317
- CDR0000350340
- COG-ADVL0317
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Childhood Acute Promyelocytic Leukemia (M3)
-
National Cancer Institute (NCI)CompletedUntreated Adult Acute Myeloid Leukemia | Adult Acute Promyelocytic Leukemia (M3) | Childhood Acute Promyelocytic Leukemia (M3) | Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) | Untreated Childhood Acute Myeloid Leukemia and Other Myeloid MalignanciesUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedAdult Acute Promyelocytic Leukemia (M3) | Childhood Acute Promyelocytic Leukemia (M3) | Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) | Adult Acute Myeloid LeukemiaUnited States
-
National Cancer Institute (NCI)TerminatedSecondary Acute Myeloid Leukemia | Childhood Acute Myeloblastic Leukemia With Maturation (M2) | Childhood Acute Promyelocytic Leukemia (M3) | Recurrent Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Myeloid LeukemiaUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)Approved for marketingRecurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8... and other conditionsUnited States
-
South China Children's Leukemia GroupCompletedChildhood Acute Promyelocytic LeukemiaChina
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedMyeloid Neoplasm | Childhood Acute Promyelocytic Leukemia With PML-RARAUnited States, Canada, Puerto Rico
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedSecondary Acute Myeloid Leukemia | Childhood Acute Myeloid Leukemia in Remission | Childhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedMyelodysplastic Syndromes | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Adult Acute Promyelocytic Leukemia (M3) | Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) | Myelodysplastic/Myeloproliferative NeoplasmsUnited States
-
National Cancer Institute (NCI)CompletedJuvenile Myelomonocytic Leukemia | Recurrent Disease | Recurrent Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Myeloid Leukemia | Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Childhood Solid Neoplasm | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia... and other conditionsUnited States, Canada
-
University of WashingtonNational Cancer Institute (NCI)CompletedAcute Myeloid Leukemia | Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) | Adult... and other conditionsUnited States
Clinical Trials on laboratory biomarker analysis
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)CompletedProstate Cancer
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingLeukemia | Acute Lymphoblastic Leukemia | Acute Promyelocytic LeukemiaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedUntreated Adult Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic LeukemiaUnited States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic LeukemiaUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedLung CancerUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed
-
Children's Oncology GroupNational Cancer Institute (NCI)WithdrawnClear Cell Renal Cell Carcinoma | Rhabdoid Tumor of the Kidney | Congenital Mesoblastic Nephroma | Childhood Kidney NeoplasmUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)WithdrawnBreast Carcinoma | BRCA1 Mutation Carrier | BRCA2 Mutation CarrierUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedWilms Tumor and Other Childhood Kidney TumorsUnited States